iRhythm Holdings, Inc.

NasdaqGS:IRTC Stock Report

Market Cap: US$4.7b

iRhythm Holdings Valuation

Is IRTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of IRTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: IRTC ($146.47) is trading above our estimate of future cash flow value ($79.16)

Significantly Below Future Cash Flow Value: IRTC is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IRTC?

Key metric: As IRTC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IRTC. This is calculated by dividing IRTC's market cap by their current revenue.
What is IRTC's PS Ratio?
PS Ratio6.7x
SalesUS$702.57m
Market CapUS$4.72b

Price to Sales Ratio vs Peers

How does IRTC's PS Ratio compare to its peers?

The above table shows the PS ratio for IRTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
GKOS Glaukos
13.7x20.44%US$6.5b
TFX Teleflex
1.5x6.62%US$4.8b
LIVN LivaNova
2.7x6.22%US$3.6b
NVST Envista Holdings
1.8x3.61%US$4.8b
IRTC iRhythm Holdings
6.7x14.88%US$4.7b

Price-To-Sales vs Peers: IRTC is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (4.9x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does IRTC's PS Ratio compare vs other companies in the US Medical Equipment Industry?

58 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY DENTSPLY SIRONA
0.8x1.97%US$2.75b
QDEL QuidelOrtho
0.7x2.87%US$1.98b
ENOV Enovis
0.6x4.90%US$1.29b
IART Integra LifeSciences Holdings
0.5x2.56%US$877.07m
IRTC 6.7xIndustry Avg. 3.1xNo. of Companies58PS03.26.49.612.816+
58 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IRTC is expensive based on its Price-To-Sales Ratio (6.7x) compared to the US Medical Equipment industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is IRTC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IRTC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.7x
Fair PS Ratio4.5x

Price-To-Sales vs Fair Ratio: IRTC is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IRTC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$146.47
US$221.27
+51.07%
6.40%US$254.00US$200.00n/a15
Feb ’27US$154.51
US$221.27
+43.21%
6.40%US$254.00US$200.00n/a15
Jan ’27US$177.44
US$218.60
+23.20%
6.70%US$244.00US$194.00n/a15
Dec ’26US$182.74
US$219.93
+20.35%
7.38%US$244.00US$194.00n/a15
Nov ’26US$187.30
US$219.93
+17.42%
7.38%US$244.00US$194.00n/a15
Oct ’26US$167.45
US$186.00
+11.08%
3.98%US$200.00US$175.00n/a14
Sep ’26US$169.98
US$182.62
+7.43%
6.02%US$200.00US$158.00n/a13
Aug ’26US$164.97
US$174.75
+5.93%
6.98%US$190.00US$147.00n/a12
Jul ’26US$145.95
US$145.92
-0.023%
8.67%US$167.00US$130.00n/a12
Jun ’26US$140.50
US$140.42
-0.059%
8.17%US$167.00US$127.00n/a12
May ’26US$108.59
US$130.92
+20.56%
8.84%US$152.00US$104.00n/a12
Apr ’26US$106.88
US$133.00
+24.44%
8.78%US$152.00US$104.00n/a12
Mar ’26US$110.16
US$133.00
+20.73%
8.78%US$152.00US$104.00n/a12
Feb ’26US$108.85
US$110.67
+1.67%
16.28%US$152.00US$86.00US$154.5112
Jan ’26US$90.17
US$105.58
+17.09%
15.73%US$152.00US$86.00US$177.4412
Dec ’25US$86.97
US$98.27
+13.00%
14.42%US$125.00US$79.00US$182.7411
Nov ’25US$75.04
US$98.27
+30.96%
14.42%US$125.00US$79.00US$187.3011
Oct ’25US$71.58
US$119.80
+67.37%
10.47%US$145.00US$100.00US$167.4510
Sep ’25US$70.88
US$117.55
+65.84%
9.33%US$145.00US$100.00US$169.9811
Aug ’25US$84.22
US$132.64
+57.49%
9.32%US$165.00US$115.00US$164.9711
Jul ’25US$106.45
US$135.45
+27.25%
8.87%US$165.00US$115.00US$145.9511
Jun ’25US$88.21
US$137.50
+55.88%
7.73%US$165.00US$122.00US$140.5010
May ’25US$111.74
US$138.50
+23.95%
6.84%US$165.00US$132.00US$108.5910
Apr ’25US$115.55
US$138.50
+19.86%
6.84%US$165.00US$132.00US$106.8810
Mar ’25US$120.52
US$138.50
+14.92%
6.84%US$165.00US$132.00US$110.1610
Feb ’25US$123.61
US$130.70
+5.74%
11.06%US$165.00US$110.00US$108.8510
US$221.27
Fair Value
33.8% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/08 19:48
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iRhythm Holdings, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PolarkBaird
David RescottBaird
Joanne WuenschBMO Capital Markets Equity Research